New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

Today's Free Fly Stories
All of the free stories from today.
Sign up for a free trial to see the rest of the stories you've been missing.
<< 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | all day >>
09:39 EDTMDRXAllscripts downgraded to Outperform from Strong Buy at Raymond James
Subscribe for More Information
09:39 EDTPGEMPly Gem IPO opens for trade at $22.35, priced at $21.00
Subscribe for More Information
09:37 EDTAAPL, GOOG, HPQ, NFLXActive equity option families trading on open
Active equity option families trading on open according to Track Data: AAPL NFLX GOOG HPQ
09:37 EDTECOMChannelAdvisor IPO indicated to open $17.00-$17.50 on 300K shares
Subscribe for More Information
09:37 EDTCSCOCisco to host a webcast
Subscribe for More Information
09:36 EDTDBDDiebold upgraded to Buy from Neutral at Sidoti
09:35 EDTTGITriumph Group management to meet with Deutsche Bank
Subscribe for More Information
09:35 EDTTSLATesla hits relative new lows, levels to watch
Subscribe for More Information
09:35 EDTOPKOPKO Health surpasses 50% enrollment in first Phase 3 trial of Rayaldy
OPKO Health has surpassed 50% enrollment in the first Phase 3 trial of Rayaldy to treat patients with secondary hyperparathyroidism, stage 3 or 4 chronic kidney disease and vitamin D insufficiency. This trial is the first of two identical randomized, double-blind, placebo controlled, multi-site studies intended to establish the safety and efficacy of RayaldyTM as a new treatment for SHPT in the targeted population. The endpoints of both studies, which will be conducted in parallel, include vitamin D status and changes in serum calcium, serum phosphorus and plasma intact parathyroid hormone. Each of the phase 3 trials will involve 210 patients recruited at approximately 40 sites in the U.S. These patients are being stratified by CKD stage and randomized in a 2:1 fashion to receive six months of treatment with either RayaldyTM or placebo. Dosing with RayaldyTM is titrated, as necessary, to achieve the desired blood concentration and the targeted reduction in PTH.
09:34 EDTCBOE Volatility Index VIX is recently up 1.12 to 14.92
Subscribe for More Information
09:34 EDTPBCTPeople's United downgraded to Sell from Hold at Sandler O'Neill
Subscribe for More Information
09:33 EDTSONSonoco Products management to meet with Deutsche Bank
Meeting to be held in London on May 23 hosted by Deutsche Bank.
09:31 EDTGLDSPDR Gold Trust rebounds, potential bullish pattern may be in play
Subscribe for More Information
09:31 EDTPPGPPG Industries management to meet with Deutsche Bank
Subscribe for More Information
09:25 EDTAAPL, SSNLFSamsung's Galaxy S4 reaches 10M channel sales
Samsung Electronics announced that global channel sales of its GALAXY S4 has surpassed 10M units sold in less than one month after its commercial debut. Launched globally on April 27 in 60 countries, the phone is estimated to be selling at a rate of four units per second.
09:25 EDTBFLYBluefly trading halted, pending news
Subscribe for More Information
09:24 EDTMBNDMultiband downgraded to Market Perform from Outperform at Northland Securities
Subscribe for More Information
09:22 EDTDOVDover upgraded to Buy from Neutral at BofA/Merrill
09:21 EDTHPQHP must diversify product options, Meg Whitman says
Subscribe for More Information
09:21 EDTHPQHewlett-Packard CEO: Still believe keeping HP together is 'right thing to do'
Subscribe for More Information
<< 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | all day >>

Sign up for a free trial to see the rest of the stories you've been missing.